Efficacy and safety of AAE581 in postmenopausal women with osteopenia/osteoporosis

Trial Profile

Efficacy and safety of AAE581 in postmenopausal women with osteopenia/osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Balicatib (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2011 Actual end date (1 Dec 2005) added as reported by ClinicalTrials.gov.
    • 02 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top